CHICAGO — Abbott Laboratories and the U.S. Food and Drug Administration have come to an agreement on the steps the company needs to take before it can restart production of infant formula at a Michigan facility, Abbott said Monday.
Abbott has entered into a consent decree with the FDA, which must still be approved in court, the company said in a news release. The exact terms of the agreement were not immediately clear Monday afternoon.
Abbott said that it expects to be able to restart production within two weeks, once the FDA determines Abbott has met the initial requirements of the agreement. Once it resumes production, Abbott could have some of its formulas produced at the plant back on store shelves within six to eight weeks after that.
